NATCOPHARM · Healthcare
The board meets on 13 Nov 2026 to approve the results. This page fills in when the numbers are filed.
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,031 cr | ₹759 cr | ₹1,068 cr | ₹1,363 cr | ₹1,371 cr | ₹475 cr | ₹1,221 cr | ₹1,329 cr | ₹1,363 cr | ₹647 cr | ₹739 cr | ₹735 cr |
| YoY | — | — | — | +20% | +33% | −37% | +14% | −2% | −1% | +36% | −39% | −45% |
| EBITDA margin | 44.4% | 35.3% | 46.5% | 59.1% | 58.6% | 8.2% | 44.9% | 43.0% | 42.5% | 24.6% | 17.3% | 25.3% |
| Other income, % of PBT | 7% | 14% | 9% | 6% | 8% | 107% | 13% | 11% | 16% | 36% | 54% | 32% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 16% | 17% | 19% | 17% | 17% | 19% | 20% | 16% | 16% | 13% | — | 34% |
| Net profit | ₹369 cr | ₹213 cr | ₹386 cr | ₹668 cr | ₹676 cr | ₹132 cr | ₹406 cr | ₹480 cr | ₹518 cr | ₹151 cr | ₹269 cr | ₹206 cr |
| YoY | — | — | — | +59% | +83% | −38% | +5% | −28% | −23% | +14% | −34% | −57% |
| Core profit YoY | — | — | — | +57% | +83% | −105% | +1% | −33% | −32% | — | −85% | −75% |
| EPS | ₹18.81 | ₹10.84 | ₹19.69 | ₹34.07 | ₹34.52 | ₹6.78 | ₹20.72 | ₹24.50 | ₹26.42 | ₹7.72 | ₹13.65 | ₹10.52 |
| Flags | · | · | · | ✓ | ✓ | 2 | ✓ | 1 | 1 | ✓ | 3 | 2 |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.